Chromotek GmbH, a Martinsried, Germany-based company that develops and markets innovative reagents for biomedical research, has raised €400,000 from High-Tech Gründerfonds and Bayern Kapital.
The investment will fund R&D activities aimed at ensuring successful market entry for chromobody technology in the field of living cell analysis.
The first products, which include screening reagents and procedures for cleaning and studying proteins for biomedical screening processes in research and the development of pharmaceutical active ingredients, are expected to reach the market as early as 2011.
Established in October 2008 as a spin-off from Munich’s Ludwig Maximilian University, Chromotek is based in Martinsried, one of Germany’s leading biotech cluster areas.
FinSMEs
15/07/2010